BPG is committed to discovery and dissemination of knowledge
Articles in Press
5/9/2025 6:47:36 AM | Browse: 24 | Download: 0
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Editorial |
Article Title |
Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass
|
Manuscript Source |
Invited Manuscript |
All Author List |
Vasily Isakov |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Russian Science Foundation |
No. 19-76-30014 |
|
Corresponding Author |
Vasily Isakov, MD, PhD, Professor, Department of Gastroenterology and Hepatology, Federal Research Center of Nutrition, Biotechnology and Food Safety, 21 Kashirskoye Shosse, Moscow 115446, Russia. vasily.isakov@gmail.com |
Key Words |
Metabolic dysfunction-associated steatotic liver disease; Skeletal muscle alterations; Sarcopenia; Skeletal muscle mass index; Myosteatosis; Dietary patterns; High-protein diet; Physical activity; Glucagon-like peptide-1 receptor agonists |
Core Tip |
Skeletal muscle alterations, such as sarcopenia, myosteatosis, and altered muscle metabolism, are highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD) and are increasingly recognized as both contributors and consequences of MASLD, affecting disease progression and outcomes. Common treatment approaches for both conditions include nutritional interventions and physical activity/exercise aimed at increasing insulin sensitivity and reducing fat mass but maintaining muscle mass and function. Pharmacological agents that target the muscle and liver (such as glucagon-like peptide-1 receptor agonists) show promise, but have not yet been approved for the treatment of MASLD. |
Citation |
Isakov V. Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass. World J Gastroenterol 2025; In press |
 |
Received |
|
2025-01-20 07:25 |
 |
Peer-Review Started |
|
2025-01-20 07:25 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-04-09 06:40 |
 |
Revised |
|
2025-04-13 12:59 |
 |
Second Decision |
|
2025-05-09 02:47 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-05-09 06:47 |
 |
Articles in Press |
|
2025-05-09 06:47 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345